Key facts
- It has raised $1.5M across 1 recorded rounds; the latest was Seed Round ($500K) in Jun 2025.
- Notable investors include Creative Destruction Lab, Cure Experience Services, Delaware Prosperity Partnership.
- BioCurie has filed 1 Form D with the SEC, most recently Jun 2025 ($500K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BioCurie
Funding rounds
1 roundsAbout BioCurie
Operator of a biotech-based company intended to improve healthcare by delivering lifesaving therapies. The company's platform leverages artificial intelligence for intelligent gene therapy production to treat and cure patients with diseases, enabling clients to improve the production of cell and gene therapies.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2021
- Employees
- 8
- Website
- biocurie.ai/
- Ownership
- Privately Held (backing)
BioCurie doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioCurie shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioCurie in its N-PORT filings yet. We sweep new filings monthly.